The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: Preclinical studies in ethanol-preferring and outbred wistar rats

Alcoholism: Clinical and Experimental Research

Volumn 22, Issue 9, 1998, Pages 2174-2185

  June, Harry L ^a   Grey, Collette ^a   Warren Reese, Connease ^a   Durr, La Franze ^a   Ricks Cord, Anila ^a   Johnson, Amanda ^a   McCane, Shannan ^a   Williams, LaShone ^a   Mason, Dynesha ^a   Cummings, Rancia ^a   Lawrence, Amanda ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Ethanol Reinforcement; Ethanol Maintained Responding; Ethanol Preferring Rats; Opioid Antagonists

Indexed keywords

NALMEFENE; NALTREXONE; OPIATE ANTAGONIST; SACCHARIN;

ALCOHOL BLOOD LEVEL; ALCOHOLISM; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRINKING BEHAVIOR; DRUG EFFECT; DRUG MECHANISM; DRUG SELF ADMINISTRATION; FEMALE; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ALCOHOL DRINKING; ALCOHOLISM; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; GENOTYPE; MALE; MOTIVATION; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, INBRED STRAINS; RECEPTORS, OPIOID;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0032407588     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000374-199812000-00038     Document Type: Article

References (46)

1. Bohn MJ, Kranzler HR, Beazoglou D, Staehler BA: Naltrexone and brief counseling to reduce heavy drinking. Am J Addict 3:91-99, 1994
2. O'Malley S, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B: Naltrexone and coping skills therapy for alcohol dependence. Arch Gen Psychiatry 49:881-887, 1992
3. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP: Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-879, 1992
4. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP: Effect of naltrexone on alcohol "high" in alcoholics. Am J Psychiatry 152:613-615, 1995
5. Froehlich JC: Genetic factors in alcohol self-administration. J Clin Psychiatry 56(Suppl. 7):15-23, 1995
6. Herz A: Endogenous opioid systems and alcohol addiction. Psychopharmacology 129:99-111, 1997
7. Reid LD, Carpenter DJ: Alcohol-abuse and alcoholism, in Reid LD (ed): Opioids, Bulimia, and Alcohol Abuse & Alcoholism. New York, Springer-Verlag, 1990, pp 23-48
8. Li T-K, Lumeng L, Doolittle P, Carr LG: Molecular associations of alcohol-seeking behavior in rat lines selectively bred for high and low voluntary ethanol drinking. Alcohol Alcohol 1(Suppl.): 121-124, 1991
9. France CP, Gerak LR: Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J Pharmacol Exp Ther 270:992-999, 1994
10. Aceto MD, Bowman ER, Harris LS, May EL: Dependence studies of new compounds in the rhesus monkey, rat, and mouse, in Proceedings, College on Problems of Drug Dependence, National Institute on Drug Abuse Research Monograph No. 132, Washington, D.C., U.S. Government Printing Office, 1986, pp 459-516
11. Aceto MD, Harris LS, May EL: Dependence studies of new compounds in the rhesus monkey, rat and mouse, in Proceedings, Committee of Problems of Drug Dependence, National Institute on Drug Abuse Research Monograph No. 67, Washington, D.C., U.S. Government Printing Office, 1986, pp 399-452
12. Dixon R, Howes J, Gentile J: Nalmefene: Intravenous safety and kinetics of a new opioid antagonist. Clin Pharmacol Ther 39:49-53, 1986
13. France CP, Woods JH: Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkey. J Pharmacol Exp Ther 250:937-943, 1989
14. Michel ME, Bolger G, Weissman BA: Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find Exp Clin Pharmacol 7:175-177, 1985
15. Barsan WG, Seger D, Danzl DF, Ling LJ, Bartlett R, Buncher R, Bryan C: Duration antagonistic effects of nalmefene and naloxone in opioid-induced sedation for emergency department procedures. Am J Emerg Med 7:155-161, 1989
16. Hahn EF, Fishman J: Narcotic antagonists: Carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists. J Med Chem 18:259-262, 1975
17. Vanvugt DA, Webb MY, Reid RL: Comparison of the duration of action of nalmefene and naloxone on the hypothalamic-pituitary axis of the rhesus monkey. Neuroendocrinology 49:275-280, 1989
18. Gal TJ, Difazio CA, Cosmo A, Dixon R: Prolonged blockade of opioid effect with oral nalmefene. Clin Pharmacol Ther 40:537-542, 1986
19. Gal TJ, Difazio CA: Prolonged antagonism of opioid action with intravenous nalmefene. Anesthesiology 64:175-180, 1986
20. Jaffe JH, Martin WR: Opioid analgesics and antagonists, in The Pharmacological Basis of Therapeutics. New York, Taylor Pergamon Press, 1990, pp 485-521
21. Wall ME, Brine DR, Perez-Reyes M: Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 9:369-375, 1981
22. Vizi ES, Folders FF, Rich J, Knoll J: The structure-action relationship and kinetics of some naloxone and naltrexone derivatives. Pharmacology 14:76-85, 1976
23. Hubbell CL, Marglin SH, Spitalnic SJ, Abelson ML, Wild KD, Reid LD: Opioidergic, serotonergic, and dopaminergic manipulations and rats' intake of a sweetened alcoholic beverage. Alcohol 8:355-367, 1991
24. Mason BJ: Dosing issues in the pharmacotherapy of alcoholism, in Proceedings of a Symposium at the Research Society on Alcoholism Annual Meeting [Pharmacotherapy of Alcoholism Update]. Alcohol Clin Exp Res 20:10A-16A, 1996
25. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E: A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 18:1162-1167, 1994
26. Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldgerg G: Preliminary dose finding studies for nalmefene treatment of alcoholism. Alcohol Clin Exp Res 18:464, 1994 (abstr A270)
27. Lumeng L, Murphy JM, McBride WJ, Li T-K: Genetic influences on alcohol preference in animals, in The Genetics of Alcoholism. New York, Oxford University Press, 1995, pp 165-201
28. June HL, Zuccarelli D, Craig KS, Delong J, Cason CR, Torres L, Murphy JM: High affinity benzodiazepine antagonists reduce responding maintained by EtOH presentation in ethanol-preferring (p) rats. J Pharmacol Exp Ther 284:1006-1914, 1998
29. Samson HH, Tolliver GA, Lumeng L, Li T-K: Ethanol reinforcement in the alcohol nonpreferring rat: Initiation using behavioral techniques without food restriction. Alcohol Clin Exp Res 13:378-385, 1989
30. Samson HH: Initiation of ethanol maintained behavior: A comparison of animal models and their implication to human drinking, in Advances in Behavioral Pharmacology: Neurobehavioral Pharmacology, vol 6. Hillsdale, NJ, Erlbaum Associates, 1987, pp 221-241
31. Weiss F, Mitchiner M, Bloom FE, Koob GF: Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology 101:178-186, 1990
32. Dixon R, Gentile J, Hsu H, Hsiao J, Howes J, Garg D, Weidler D: Nalmefene: Safety and kinetics after single and multiple oral doses of a new opioid antagonist. Clin Pharmacol 27:233-239, 1987
33. Gardell LR, Whalen CA, Chattophadyay S, Cavallaro CA, Hubbell CL, Reid LD: Combination of naltrexone and fluoxetine on rats propensity to take alcoholic beverage. Alcohol Clin Exp Res 21:1435-1439, 1997
34. Lee MC, Wagner HN Jr, Tanada S, Frost JJ, Bice AN, Dannals RF: Duration of occupancy of opioid receptors by naltrexone. J Nucl Med 29:1207-1211, 1988
35. Cone EJ, Gordetzky CW, Yeh SY: The urinary excretion profile of naltrexone and metabolites in man. Drug Metab Dispos 2:506-512, 1974
36. Meyer MC, Straughn AB, et al: Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 45:15-19, 1984
37. Verebey K, Volavka J, Mule SJ, et al: Naltrexone: Disposition, metabolism and effects after acute and chronic dosing. Clin Pharmacol Ther 20:315-328, 1976
38. Arunlakshana O, Schild HO: Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58, 1959
39. 2 analysis. J Pharmacol Exp Ther 243:591-596, 1987
40. Takemori AE: Determination of pharmacological constants: Use of narcotic antagonists to characterize analgesic receptors in Narcotic Antagonists, Advances in Biochemical Psychopharmacology, vol 8. New York, Raven Press, 1974, pp 335-344
41. Teal JJ, Holtzman SG: Stimulus effects of morphine in the monkey: Quantitative analysis of antagonism. Pharmacol Biochem Behav 12:587-593, 1980
42. De Haven-Hudkins DL, Bromstrom FA, Allen JT, Lesko LJ, Ferkany JW, Kaplita PV, Mavunkel BJ, Rzeszotarski WJ, Steranka LR: Pharmacologic profile of NPC 168 (naltrexonephenyl oxime), a novel compound with activity at opioid receptors. Pharmacol Biochem Behav 37:497-504, 1990
43. Wagner HN Jr, Burns HD, Dannals RF, et al: Imaging dopamine receptors in the human brain by positron tomography. Science 221:1264-1266, 1983
44. Wagner HN Jr: Quantitative imaging of neuroreceptors in the living human brain. Semin Nucl Med 16:51-62, 1986
45. Reid LD, Gardell LR, Chattopadhyay S, Hubbell CL: Periodic naltrexone and propensity to take alcoholic beverage. Alcohol Clin Exp Res 20:1329-1334, 1996
46. Colburn WA: Pharmacokinetic and biopharmaceutic parameters during enterohepatic circulation of drugs. J Pharmacol Sci 71:131-133, 1982